Brent will share insights from his role as the Chief Business Officer and US General Manager of OncoOne, the world’s experts in developing therapies targeting the macrophage migration inhibitory factor, or MIF, for patients with solid tumors and severe inflammatory conditions.
Brent Meadows has over 25 years of US and Global commercial strategy, launch marketing, and business development experience from both large and small biotechnology companies including Johnson & Johnson, Bristol-Myers Squibb, Regeneron, and Biogen. He joined OncoOne this fall as their Chief Business Officer and US General Manager responsible for OncoOne’s partnerships, collaborations, and business development efforts. He was the first commercial hire in 2007 for AVEO Oncology where he served as co-program executive for FOTIVDA® (tivozanib) helping to create the scientific narrative and expert engagement which led to the $1.4 billion collaboration with Astellas and the EMEA approval. Mr. Meadows holds an MBA from the Babson F.W. Olin Graduate School of Business and a Bachelors of Business Administration from the University of Richmond.
_________________________________________________________________________________________
Open networking will follow the presentation for those interested. Participants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room.
***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.
